Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Equillium (Nasdaq: EQ) announced an inducement grant on April 1, 2026: the Compensation Committee awarded a nonstatutory stock option for 32,000 shares to a new employee under the company’s 2024 Inducement Plan.

The option’s exercise price equals $2.04 (closing price on April 1, 2026) and vests over four years: 25% after one year then monthly over 36 months, subject to continued service and plan terms.

AI-generated analysis. Not financial advice.

News Market Reaction – EQ

+2.03%

1 alert

+2.03% News Effect

On the day this news was published, EQ gained 2.03%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Shelf registration size: $250,000,000 ATM program size: $75,000,000 Inducement shares: 32,000 shares +4 more

7 metrics

Shelf registration size $250,000,000 Form S-3 shelf filed Nov 13, 2025

ATM program size $75,000,000 At-the-market offering capacity within S-3 shelf

Inducement shares 32,000 shares Nonstatutory stock options to new employee under 2024 Inducement Plan

Option exercise price $2.04 Exercise price equals EQ closing price on April 1, 2026

Vesting period 4 years Inducement stock options vest over four years

Initial vesting cliff 25% 25% of shares vest on one-year anniversary of vesting commencement

Remainder vesting schedule 36 months Remaining 75% vests monthly over 36 months thereafter

Market Reality Check

Price: $2.77 Vol: Volume 353,720 is 0.53x t...

low vol

$2.77 Last Close

Volume Volume 353,720 is 0.53x the 20-day average of 664,773, indicating subdued trading interest pre‑announcement. low

Technical Shares at $2.04 are trading above the 200-day MA of $1.26 and about 24% below the $2.70 52-week high, after rebounding strongly from the $0.27 52-week low.

Peers on Argus

EQ was up about 2% while peers showed mixed moves: BMEA −2.61%, CRBP +5.5%, FATE...

EQ was up about 2% while peers showed mixed moves: BMEA −2.61%, CRBP +5.5%, FATE +1.64%, AVTX +9.94%, ZURA +1.01%. With no peers in the momentum scanner and only one peer (FATE) sharing similar inducement‑award news, trading appeared more company‑specific than part of a broad sector move.

Common Catalyst Both EQ and FATE reported employee inducement awards under Nasdaq Listing Rule 5635(c)(4), suggesting a routine HR‑driven theme rather than a fundamental sector catalyst.

Historical Context

5 past events · Latest: Mar 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 25	Earnings and outlook	Neutral	+0.0%	Reported 2025 results, zero revenue, net loss and cash runway into 2029.
Mar 18	Conference participation	Neutral	-0.9%	Announcement of fireside chat and investor meetings at Roth conference.
Mar 13	PIPE financing	Positive	+19.3%	Approximately $35M private placement to fund EQ504 and extend cash runway.
Feb 25	Conference participation	Neutral	-4.7%	Participation in Leerink Global Healthcare Conference and investor meetings.
Feb 02	Inducement grants	Neutral	+0.0%	Inducement stock options for 59,750 shares granted to two new employees.

Pattern Detected

Recent news (financing, conferences, inducement grants) has mostly seen modest or neutral price reactions, with the notable exception of a strong positive move on the March 2026 PIPE financing.

Recent Company History

Over the last few months, Equillium has shifted toward a development‑stage focus and strengthened its balance sheet. On Feb 2, it reported similar inducement stock option grants. March brought conference participation announcements and a $35M PIPE on Mar 13 that lifted shares by 19.32%. Earnings on Mar 25 highlighted a $22.4M net loss and no 2025 revenue but confirmed cash runway into 2029. Today’s small inducement grant continues this pattern of incremental, largely non‑disruptive updates.

Regulatory & Risk Context

Active S-3 Shelf · $250,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-13

$250,000,000 registered capacity

Equillium has an effective Form S-3 shelf filed on Nov 13, 2025 allowing up to $250,000,000 of securities, including an at-the-market program of up to $75,000,000 in common stock through LifeSci Capital. Usage count is 0, so the full registered capacity remains available for potential future capital raises.

Market Pulse Summary

This announcement details a routine inducement stock option grant for 32,000 shares at an exercise p...

Analysis

This announcement details a routine inducement stock option grant for 32,000 shares at an exercise price of $2.04, vesting over four years under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). It follows earlier inducement grants and recent financings, including a $35M private placement and an effective $250,000,000 shelf with a $75,000,000 ATM. Investors monitoring Equillium typically track equity issuance, cash runway into 2029, and progress on the EQ504 program.

Key Terms

nasdaq listing rule 5635(c)(4), nonstatutory stock options, inducement award

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"approved the stock option as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

nonstatutory stock options financial

"granted an inducement award consisting of nonstatutory stock options to purchase a total of 32,000 shares"

A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.

inducement award financial

"granted an inducement award consisting of nonstatutory stock options to purchase a total of 32,000 shares"

An inducement award is a special cash or equity payment given to a new hire—often an executive or key employee—outside the company’s regular pay plans to persuade them to join. Think of it like a signing bonus that can align the new person’s goals with shareholders but also represents a cost and can reduce existing owners’ percentage of the company, so investors watch these awards for their impact on ownership and future performance.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2026, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 32,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price per share equal to $2.04, Equillium’s closing stock price on April 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Equillium through the applicable vesting dates. The stock option is subject to the terms and conditions of Equillium’s 2024 Inducement Plan and the terms and conditions of an applicable stock option agreement covering the grant.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways. 

For more information, visit www.equilliumbio.com.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", “could”, “continue”, "expect", "estimate", “may”, "plan", "outlook", “future” and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical studies; and whether the results from clinical studies will validate and support the safety and efficacy of Equillium’s product candidates. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact 
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com

FAQ

What stock option did Equillium (EQ) grant on April 1, 2026?

Equillium granted a nonstatutory stock option to purchase 32,000 shares to a new employee. According to the company, the grant was made under its 2024 Inducement Plan and approved as an inducement material to employment under Nasdaq Rule 5635(c)(4).

What is the exercise price for Equillium (EQ) inducement options dated April 1, 2026?

The exercise price is $2.04 per share, equal to the closing stock price on April 1, 2026. According to the company, that price sets the option strike and governs option exercise calculations under the option agreement.

How do the Equillium (EQ) inducement options vest and when do shares become exercisable?

The option vests over a four-year schedule: 25% after one year, then monthly over the next 36 months. According to the company, vesting is contingent on the new employee’s continued service through each applicable vesting date.

Under which plan were Equillium (EQ) inducement options granted on April 1, 2026?

The grant was made under Equillium’s 2024 Inducement Plan. According to the company, the option is subject to that plan’s terms and the applicable stock option agreement covering the grant.

Was the Equillium (EQ) April 1, 2026 grant compliant with Nasdaq rules?

Yes, the Compensation Committee approved the award as an inducement under Nasdaq Listing Rule 5635(c)(4). According to the company, the approval confirms the grant was treated as material to the new employee’s employment.